about
Unveiling changes in the landscape of patient populations in cancer early drug developmentNutrients in Energy and One-Carbon Metabolism: Learning from Metformin Users.Rosiglitazone reduces breast cancer risk in Taiwanese female patients with type 2 diabetes mellitus.Metformin inhibits RANKL and sensitizes cancer stem cells to denosumab.Metformin Potentiates the Benefits of Dietary Restraint: A Metabolomic Study.Fatty acid synthase (FASN) as a therapeutic target in breast cancer.Glyoxalase 1 sustains the metastatic phenotype of prostate cancer cells via EMT control.Development of an Injectable Slow-Release Metformin Formulation and Evaluation of Its Potential Antitumor Effects.
P2860
Q28073826-89E2FF7F-7285-4B98-B392-3204EC38B951Q37673171-706DD813-25C8-4702-B6F7-7E9D48A5B126Q37709423-E5416B5F-A2A4-47B1-B8DB-66B1387D2466Q42508259-6DEBB468-A067-46CB-B511-6F48C2F584F7Q47169063-168827EE-4B43-4083-8DDE-F86A0728EEE8Q50044384-C30C3B25-FB67-40AA-A05D-2E204E12983DQ52674354-703DC3C9-49E3-426E-AD85-34F9ABDCCC25Q52676408-2CC54DBC-497F-4EB7-9CA6-DC115A79CFFD
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 23 June 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Metformin and cancer: Quo vadis et cui bono?
@en
Metformin and cancer: Quo vadis et cui bono?
@nl
type
label
Metformin and cancer: Quo vadis et cui bono?
@en
Metformin and cancer: Quo vadis et cui bono?
@nl
prefLabel
Metformin and cancer: Quo vadis et cui bono?
@en
Metformin and cancer: Quo vadis et cui bono?
@nl
P2860
P356
P1433
P1476
Metformin and cancer: Quo vadis et cui bono?
@en
P2093
Javier A Menendez
Jorge Joven
P2860
P304
54096-54101
P356
10.18632/ONCOTARGET.10262
P407
P577
2016-06-23T00:00:00Z